SCHEDULE: Vanguard Group Amends Incyte Stake to Zero After Realignment

The Vanguard Group has amended its Schedule 13G filing for Incyte Corp, reporting zero beneficial ownership following an internal realignment that disaggregated reporting.

Summary

• The Vanguard Group filed Amendment No. 11 to its Schedule 13G for Incyte Corp (CUSIP: 45337C102).
• The filing indicates that The Vanguard Group now beneficially owns 0% of Incyte Corp's common stock, with zero sole or shared voting and dispositive power.
• This change stems from an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these newly disaggregated subsidiaries and/or business divisions.
• These subsidiaries and/or business divisions continue to pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing by The Vanguard Group, reflecting an internal organizational change rather than a change in investment thesis for Incyte Corp. It has no direct positive or negative implications for Incyte's operational or financial performance.

Future Outlook

No forward-looking statements or guidance regarding Incyte Corp's operations or financial performance are provided in this filing. The filing pertains solely to The Vanguard Group's beneficial ownership reporting structure.

Management Comments

• "On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment."
• "In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release."
• "These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment."
• "Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions."

Industry Context

StockSavvy.ai notes that institutional investors like The Vanguard Group frequently adjust their internal reporting structures and beneficial ownership aggregation methods. This disaggregation, often in compliance with SEC guidance, is a common practice for large asset managers and does not necessarily reflect a change in investment strategy or sentiment towards the underlying company, Incyte Corp.

Stakeholder Impact

• Shareholders of Incyte Corp: Minimal direct impact, as the underlying investment by Vanguard's broader entities likely remains, just reported differently.
• The Vanguard Group: Internal operational change for reporting purposes, ensuring compliance with SEC guidelines for disaggregated reporting.

Next Steps

• Certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report their beneficial ownership of Incyte Corp separately.

Key Dates

Keywords

Incyte Corp, Vanguard Group, Schedule 13G, Beneficial Ownership, SEC Filing, Institutional Investor, Common Stock, Realignment